Artivion Q2 revenue $89.3M (+11% YoY); raises FY revenue guidance to $342-350M

ARTIVION, INC.

2023-Q2 EPS reported -$0.41 revenue$172,480,000

Net loss ($3.4M) or ($0.08)/share; non-GAAP net income $2.3M ($0.06)/share.
Non-GAAP adjusted EBITDA $13.8M, up 35% YoY.
Aortic stent graft revenue +19% YoY; On-X +11% constant currency.
Received $14.3M PerClot PMA approval milestone payment from Baxter.
FY 2023 constant currency revenue growth guidance raised to 10%-12%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ARTIVION, INC. reported the second quarter ended June 30, 2023 results: revenue $89.3 million, net income ($3.4) million, EPS ($0.08) per share. Guidance raised.

Period: the second quarter ended June 30, 2023
Revenue: $89.3 million
Net income: ($3.4) million
EPS: ($0.08) per share
Guidance: raised
Result: reported results

Exact text from the filing

• Achieved revenue of $89.3 million in the second quarter of 2023 versus $80.3 million in the second quarter of 2022, an increase of 11% on both a GAAP and non-GAAP constant currency basis • Net loss was ($3.4) million or ($0.08) per share;

View on SEC.gov

Browse all earnings releases →

ARTIVION, INC. filing history →

Source: SEC EDGAR

accession 0000784199-23-000130

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.